BioCentury
ARTICLE | Clinical News

AKB-9778: Phase Ib/IIa data

November 11, 2013 8:00 AM UTC

An open-label, dose-escalation, U.S. Phase Ib/IIa trial in 24 patients with DME showed that once-daily subcutaneous AKB-9778 for 28 days was well tolerated and produced "meaningful" changes in retinal...